Pacira Expands Asian Footprint with LG Chem Distribution Deal
Event summary
- Pacira BioSciences has partnered with LG Chem to distribute EXPAREL® in select Asian-Pacific markets.
- LG Chem secures exclusive commercialization rights for EXPAREL® in the licensed territories.
- Pacira will manufacture EXPAREL®, while LG Chem handles regulatory approvals and market entry.
- LG Chem plans to file for marketing authorizations in South Korea and Thailand within six months.
- Pacira will receive an undisclosed upfront payment, transfer pricing, and tiered royalties.
The big picture
This partnership represents Pacira’s continued push to expand EXPAREL’s global reach beyond its established North American market. LG Chem’s existing orthopedic pain management infrastructure provides Pacira with a shortcut to market penetration in a region with significant unmet needs for non-opioid pain control, but also introduces reliance on a third party for commercial execution. The deal’s financial terms remain opaque, making it difficult to assess the true value of the arrangement.
What we're watching
- Regulatory Hurdles
- The speed of regulatory approvals in South Korea and Thailand will be a key indicator of the partnership's success and LG Chem’s execution capabilities.
- Market Adoption
- How quickly EXPAREL gains traction within the Asian-Pacific market, particularly given existing analgesic preferences, will determine the financial upside for both Pacira and LG Chem.
- Financial Impact
- The undisclosed upfront payment and tiered royalty structure will need to be substantial to justify the ceded exclusivity and offset Pacira’s manufacturing costs.
Related topics